Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the ...

If you have atopic dermatitis (eczema), this guide will help you prepare for what to except during your initial doctor's appointment, including questions to ask, tests that might be ordered, and how ...

Nektar Therapeutics (NKTR) stock climbed as Jefferies upgraded the company to buy ahead of a Phase 2b trial readout for ...

The visible symptoms only scratch the surface of this chronic skin condition Living with a chronic condition like atopic ...

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

Conduit Pharmaceuticals (CDT) announces the filing of two groundbreaking patents for tapinarof, VTAMA, including a dual active cocrystal, ...

Jefferies upgraded Nektar (NKTR) to Buy from Hold with a price target of $2, up from $1. The company’s rezpegaldesleukin will report topline ...